Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma.
Pigment Cell Melanoma Res
; 32(2): 237-247, 2019 03.
Article
in En
| MEDLINE
| ID: mdl-30216694
ABSTRACT
This review will focus on the role of the tumor microenvironment (TME) in the development of drug resistance in melanoma. Resistance to mitogen-activated protein kinase inhibitors (MAPKi) in melanoma is observed months after treatment, a phenomenon that is often attributed to the incredible plasticity of melanoma cells but may also depend on the TME. The TME is unique in its cellular composition-it contains fibroblasts, immune cells, endothelial cells, adipocytes, and among others. In addition, the TME provides "non-homeostatic" levels of oxygen, nutrients (hypoxia and metabolic stress), and extracellular matrix proteins, creating a pro-tumorigenic niche that drives resistance to MAPKi treatment. In this review, we will focus on how changes in the tumor microenvironment regulate MAPKi resistance.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Resistance, Neoplasm
/
Molecular Targeted Therapy
/
Tumor Microenvironment
/
Melanoma
Limits:
Animals
/
Humans
Language:
En
Journal:
Pigment Cell Melanoma Res
Journal subject:
NEOPLASIAS
Year:
2019
Document type:
Article